Trial Profile
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Capecitabine; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Carcinoma; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 06 Jun 2023 Results assessing Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 10 Apr 2020 Primary endpoint (5-year disease free survival) has been met, according to results published in the Journal of Clinical Oncology
- 10 Apr 2020 Results (data cutoff date: 19 March 2020) were published in the Journal of Clinical Oncology